An Analytical real-world study assessing prevalence of adverse effects associated with vaccination against SARS-CoV2 in patients with chronic liver diseases
Latest Information Update: 14 Jan 2022
At a glance
- Drugs COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 14 Jan 2022 New trial record
- 15 Nov 2021 Results presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases